Yes. The article helps answer (as much as is possible) much that...

Yes. The article helps answer (as much as is possible) much that has been hypothesized/questioned on this forum.

For example, we had a recent discussion brought up by a whole bunch of downrampers questioning which patients recieved the Remestemcel-L treatment, some even suggesting that the patients were not intubated.

Answer from Si: "Under the protocol, patients come into intensive care and received standard-of-care treatment. Once they were intubated on a ventilator, they were treated within 72 hours with two infusions of Mesoblast’s remestemcel-L cells within five days."

And again...have the trials begun? How far off are they? When will we know if it works?

Answer from Si: The FDA has approved the same protocol for the phase II/III trial, and it will be powered so that results will be “self-evident,” Itescu said, noting that the trial will begin “imminently” in 20 to 30 sites across the U.S.

“We’ll know very fast if we’re seeing the same survival benefit in a randomized trial,” the CEO said.


Can't wait to find out!